Trials / Unknown
UnknownNCT04326829
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate Efficacy and Safety of QL1604 Monotherapy for the Treatment of Unresectable or Metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability-high (MSI-H) Solid Tumors That Failed to Respond to Standard Therapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1604 | QL1604, IV infusion |
Timeline
- Start date
- 2020-07-08
- Primary completion
- 2022-12-01
- Completion
- 2023-07-01
- First posted
- 2020-03-30
- Last updated
- 2022-12-07
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04326829. Inclusion in this directory is not an endorsement.